AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
== Clinical significance == Disorders of capillary formation as a developmental defect or acquired disorder are a feature in many common and serious disorders. Within a wide range of cellular factors and cytokines, issues with normal genetic expression and bioactivity of the vascular growth and permeability factor vascular endothelial growth factor (VEGF) appear to play a major role in many of the disorders. Cellular factors include reduced number and function of bone-marrow derived endothelial progenitor cells. and reduced ability of those cells to form blood vessels.
Peptide nucleic acids (PNAs) are synthetic oligonucleotides in which the sugar-phosphate backbone of the DNA or RNA is replaced by a neutral N-(2-aminoethyl)-glycine peptide-like backbone. This allows PNAs to hybridize with complementary DNA or RNA with high affinity and specificity, maintaining their ability to be amplified via polymerase chain reaction (PCR). Unlike DNA/RNA, PNAs are able to resist degradation by nucleases and proteases. In a PNA-encoded library system, unique PNA sequences serve as molecular tags that are covalently attached to small molecules that are produced using combinatorial methods that generate large collections of related compounds. These PNA tags act as barcodes that encode the identity of the PNA allowing for downstream identification. PNA libraries are synthesized using solid-phase peptide synthesis (SPPS), allowing library assembly on resin similar to other peptide libraries. This contrasts with DNA-encoded libraries, which often require enzymatic ligation steps and can be limited by the chemical properties of DNA. The neutrality and stability of the PNA backbone means that PNA tags can tolerate conditions that might degrade DNA tags, and the strong hybridization to complementary nucleic acids which allows PNA tags to be decoded wither by direct hybridization or by conversion into DNA, which can then be amplified and analyzed ,<ref. PNA-encoded libraries have been used in several different formats, including microarray hybridization, selection against biological targets, and PCR-based decoding following selection.
Sertraline is a selective serotonin reuptake inhibitor (SSRI). By binding to the serotonin transporter (SERT) it inhibits neuronal reuptake of serotonin and potentiates serotonergic activity in the central nervous system. Over time, this leads to a downregulation of pre-synaptic 5-HT1A receptors, which is associated with an improvement in passive stress tolerance, and delayed downstream increase in expression of brain-derived neurotrophic factor (BDNF), which may contribute to a reduction in negative affective biases. It does not significantly affect histamine, acetylcholine, GABA or benzodiazepine receptors. Sertraline also shows relatively high activity as an inhibitor of the dopamine transporter (DAT) occupying ~20% of DAT receptors at doses 200mg and above, and antagonist of the sigma σ1 receptor (but not the σ2 receptor). However, sertraline affinity for its main target (SERT) is much greater than its affinity for σ1 receptor and DAT. Although there could be a role for the σ1 receptor in the pharmacology of sertraline, the significance of this receptor in its actions is unclear. Similarly, the clinical relevance of sertraline's blockade of the dopamine transporter is uncertain. Sertraline is a REDD1-dependent mTOR inhibitor. It blocks AKT/mTOR pathway and has autophagy-inducing activity.
A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (a.k.a. shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. Shingles provokes a painful rash with blisters and can be followed by chronic pain (postherpetic neuralgia) and other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination. Two zoster vaccines have been approved for use in people over 50 years old. Shingrix (GSK) is a recombinant subunit vaccine that has been used in many countries since 2017. Zostavax (Merck), in use since 2006, is an attenuated vaccine which consists of a larger-than-normal dose of varicella vaccine. Unlike Shingrix, Zostavax is not suitable for people with immunosuppression or diseases that affect the immune system. Zostavax was discontinued in the United States in November 2020. Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent. Varicella vaccine is used to prevent diseases caused by the same virus.
Sources: en.wikipedia.org
=== Pneumatic elevator === A pneumatic elevator consists of a cylindrical vertical shaft (typically made of transparent plastic), and a passenger capsule (also transparent) within the shaft which moves vertically by means of differential air pressure above and below. The main advantage that it requires neither a pit below or a loft above the shaft. For ascending operations, a vacuum pump at the top of the elevator shaft creates a low pressure by drawing air from above the capsule while below the greater normal atmospheric pressure is permitted to enter at the lower (ground floor) level below the capsule providing lift. To descend, electronically controlled valves inside the tubular shaft regulate the entry and exit of air within the cylinder lowering the car smoothly by means of programmed operation. In the event of a failure of the vacuum pump or electronically controlled valves, the trapped volume of air below the capsule acts as a cushion that is allowed to slowly escape by means of a mechanical valve, gently returning the capsule to the lowest level.
=== Pharmacodynamics === The 3,6-diesters of morphine are drugs with more rapid and complete central nervous system penetration due to increased lipid solubility and other structural considerations. The prototype for this subgroup of semi-synthetic opiates is heroin and the group also includes dipropanoylmorphine, diacetyldihydromorphine, disalicylmorphine and others. Whilst this produces an enhanced "bang", i.e. a faster and more sudden onset of action when the drug is administered intravenously, it cannot be distinguished from morphine via other routes, although the different side effect profile, including lower incidence of nausea, is very apparent.
St. John's wort affects the clearance of numerous drugs, including cyclosporin, SSRI antidepressants, digoxin, indinavir, and phenprocoumon. It may also interact with the anti-cancer drugs irinotecan and imatinib. Salvia miltiorrhiza may enhance anticoagulation and bleeding among people taking warfarin. Allium sativum has been found to decrease the plasma concentration of saquinavir, and may cause hypoglycemia when taken with chlorpropamide. Ginkgo biloba can cause bleeding when combined with warfarin or aspirin. Concomitant Ephedra and caffeine use has been reported to, in rare cases, cause fatalities.
=== March === March 2 A major car crash in Imperial County, California kills 13 people and injures 13 others. COVID-19 pandemic Against CDC warnings, Texas Governor Greg Abbott lifts the statewide mask requirement and allows businesses to open at 100% capacity beginning March 10. Oregon reports its first cases of the Lineage P.1 variant in two people from Douglas County who previously traveled to Brazil. March 5 COVID-19 pandemic Illinois reports its first case of the Lineage P.1 variant first detected in Brazil in a person from Chicago. Tennessee reports its first case of the 501.V2 variant first detected in South Africa. March 6 – The Senate passes the American Rescue Plan Act, President Biden's $1.9 trillion COVID-19 relief package. March 7 – March 2021 Hawaii floods – Floods in Hawaii leave one missing, destroy six homes, force evacuations, and leave 1,300 without electricity. March 8 Missouri Senator Roy Blunt announces he will not run for re-election in 2022. The trial for Derek Chauvin, a former police officer involved in the murder of George Floyd last May, begins with jury selection. COVID-19 pandemic Hawaii reports its first case of South Africa's 501.V2 variant in an Oahu resident with no travel history. Michigan reports its first case of the 501.V2 variant in a child from Jackson County. March 10 COVID-19 pandemic Michigan surpasses 600,000 confirmed cases of COVID-19. New Jersey reports its first case of 501.V2 variant first detected in South Africa.
Efficiency factor (N) practically measures how sharp component peaks on the chromatogram are, as ratio of the component peak's area ("retention time") relative to the width of the peaks at their widest point (at the baseline). Peaks that are tall, sharp, and relatively narrow indicate that separation method efficiently removed a component from a mixture; high efficiency. Efficiency is very dependent upon the HPLC column and the HPLC method used. Efficiency factor is synonymous with plate number, and the 'number of theoretical plates'. Retention factor (kappa prime) measures how long a component of the mixture stuck to the column, measured by the area under the curve of its peak in a chromatogram (since HPLC chromatograms are a function of time). Each chromatogram peak will have its own retention factor (e.g., kappa1 for the retention factor of the first peak). This factor may be corrected for by the void volume of the column. Separation factor (alpha) is a relative comparison on how well two neighboring components of the mixture were separated (i.e., two neighboring bands on a chromatogram). This factor is defined in terms of a ratio of the retention factors of a pair of neighboring chromatogram peaks, and may also be corrected for by the void volume of the column. The greater the separation factor value is over 1.0, the better the separation, until about 2.0 beyond which an HPLC method is probably not needed for separation.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.